AKYA Akoya Biosciences
- 4.120
- -0.145-3.40%
- 3.300
- -0.820-19.90%
Akoya Biosciences News
Changes in US stocks 丨 Akoya fell 20.6% before the market, and Q1 losses exceeded expectations, and full-year revenue guidance fell short of expectations
Greenhui, May 14 | Space biology company Akoya (AKYA.US) fell 20.6% to $3.27 before the market. The company lost $23.5 million in the first quarter compared to an expected loss of $14.3 million. In the same period last year, Akoya lost $18.8 million. Akoya's revenue of $18.4 million was lower than analysts' estimates of $24.3 million, down from $21.4 million last year. Revenue for this year is expected to be between $104 million and $112 million, compared to Wall Street's estimate of $115.7 million.
Akoya Biosciences Sinks Over 30% in Late-Hours Activity Monday as Q1 Sales Miss Capital IQ Estimate
03:45 AM EDT, 05/14/2024 (MT Newswires) -- Akoya Biosciences Sinks Over 30% in Late-Hours Activity Monday as Q1 Sales Miss Capital IQ Estimate Price: 2.8500, Change: -1.27, Percent Change: -30.83
Stocks to Watch: Akoya Biosciences, Harrow, Augmedix
By Ben Glickman Akoya Biosciences said that first-quarter results fell short of expectations because of pressure on capital expenditures, deferred revenue at a pharmaceutical partner's lab and issues
Shares of Akoya Biosciences Drop After 1Q Earnings, Revenue Outlook Miss
By Adam L. Cataldo Shares of Akoya Biosciences tumbled after the spatial biology company's first-quarter results and its outlook for revenue this year fell short of analysts' estimates. The stock dr
INFN, VYGR and AMSC Are Among After Hour Movers
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ
Akoya BioSciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Akoya BioSciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Akoya Biosciences Q1 2024 Adj EPS $(0.39) Misses $(0.29) Estimate, Sales $18.350M Miss $24.281M Estimate
Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.29) by 34.48 percent. The company reported quarterly sales of $18.350
Earnings Flash (AKYA) AKOYA BIOSCIENCES Reports Q1 Revenue $18.4M, Vs. Street Est of $24.3M
04:01 PM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (AKYA) AKOYA BIOSCIENCES Reports Q1 Revenue $18.4M, vs. Street Est of $24.3M
Akoya Biosciences Sees FY24 Rev $104M-$112M >AKYA
Akoya Biosciences Sees FY24 Rev $104M-$112M >AKYA
Akoya Biosciences 1Q Loss/Shr 48c >AKYA
Akoya Biosciences 1Q Loss/Shr 48c >AKYA
Akoya Biosciences and NeraCare Enter Into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company, and NeraCare, a leading developer of laboratory tests for the
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company, has opened its Operations and Manufacturing Center of Excellence in Marlborough,
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company, today announced that it will release financial results for the first quarter of
Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting With Case Studies Demonstrating Unprecedented Speed and Scale
MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company, today announced it will highlight case studies featuring its Spatial Biol
Akoya Biosciences(AKYA.US) Officer Sells US$37,242.75 in Common Stocks
$Akoya Biosciences(AKYA.US)$ Officer McKelligon Brian sold 7,500 shares of Common Stocks on Mar 20, 2024 at an average price of $4.9657 for a total value of $37,242.75.Source: Announcement What is sta
(SEC Amendment) Akoya Biosciences(AKYA.US) Officer Sells US$37,042.5 in Common Stocks
$Akoya Biosciences(AKYA.US)$ Officer McKelligon Brian sold 7,500 shares of Common Stocks on Mar 13, 2024 at an average price of $4.939 for a total value of $37,042.5.Source: Announcement What is state
Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider
Bringing End-to-End Spatial Biology Solutions to Life Sciences Researchers for Advanced Spatial Proteomics AnalysisWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecula
Akoya Biosciences(AKYA.US) Officer Sells US$37,035 in Common Stocks
$Akoya Biosciences(AKYA.US)$ Officer McKelligon Brian sold 7,500 shares of Common Stocks on Mar 13, 2024 at an average price of $4.938 for a total value of $37,035.Source: Announcement What is stateme
Analysis
Price Target
No Data
